Who are IMOVAX Polio™: Inactivated Poliomyelitis Vaccine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): IPV at 6 weeks of age, EV71 Vaccine only, Healive® Lot 3, COVAX only (1st and 2nd dose), V - C - C+V, Inactivated COVID-19 Vaccine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/imovax-polio-inactivated-poliomyelitis-vaccine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

IMOVAX Polio™: Inactivated Poliomyelitis Vaccine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

IMOVAX Polio™: Inactivated Poliomyelitis Vaccine (IMOVAX Polio™: Inactivated Poliomyelitis Vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inactivated viral vaccine. Area: Immunology / Infectious Disease.

marketed Inactivated viral vaccine Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

IMOVAX Polio™: Inactivated Poliomyelitis Vaccine (IMOVAX Polio™: Inactivated Poliomyelitis Vaccine) — Sanofi Pasteur, a Sanofi Company. IMOVAX Polio stimulates the immune system to produce antibodies against all three poliovirus types by introducing inactivated (killed) poliovirus particles.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
IMOVAX Polio™: Inactivated Poliomyelitis Vaccine TARGET	IMOVAX Polio™: Inactivated Poliomyelitis Vaccine	Sanofi Pasteur, a Sanofi Company	marketed	Inactivated viral vaccine
IPV at 6 weeks of age	IPV at 6 weeks of age	Centers for Disease Control and Prevention	marketed	Inactivated viral vaccine	Poliovirus types 1, 2, and 3
EV71 Vaccine only	EV71 Vaccine only	Sinovac Biotech Co., Ltd	marketed	Inactivated viral vaccine	Enterovirus 71 (EV71) viral antigens
Healive® Lot 3	Healive® Lot 3	Sinovac Biotech Co., Ltd	marketed	Inactivated viral vaccine	Hepatitis A virus surface antigens
COVAX only (1st and 2nd dose)	COVAX only (1st and 2nd dose)	China National Biotec Group Company Limited	marketed	Inactivated viral vaccine	SARS-CoV-2 spike protein and other viral antigens
V - C - C+V	V - C - C+V	IlDong Pharmaceutical Co Ltd	marketed	Inactivated viral vaccine
Inactivated COVID-19 Vaccine	Inactivated COVID-19 Vaccine	Sinovac Research and Development Co., Ltd.	marketed	inactivated viral vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inactivated viral vaccine class)

Sinovac Biotech Co., Ltd · 9 drugs in this class
Sanofi Pasteur, a Sanofi Company · 9 drugs in this class
GlaxoSmithKline · 5 drugs in this class
Valneva Austria GmbH · 4 drugs in this class
Medical University of Vienna · 3 drugs in this class
Centers for Disease Control and Prevention · 3 drugs in this class
China National Biotec Group Company Limited · 2 drugs in this class
Statens Serum Institut · 2 drugs in this class
Institute of Medical Biology, Chinese Academy of Medical Sciences · 2 drugs in this class
Crucell Holland BV · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IMOVAX Polio™: Inactivated Poliomyelitis Vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/imovax-polio-inactivated-poliomyelitis-vaccine. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab